ATE183514T1 - Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten - Google Patents

Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten

Info

Publication number
ATE183514T1
ATE183514T1 AT93913627T AT93913627T ATE183514T1 AT E183514 T1 ATE183514 T1 AT E183514T1 AT 93913627 T AT93913627 T AT 93913627T AT 93913627 T AT93913627 T AT 93913627T AT E183514 T1 ATE183514 T1 AT E183514T1
Authority
AT
Austria
Prior art keywords
human
protein
pct
lymphocytes
peptides
Prior art date
Application number
AT93913627T
Other languages
English (en)
Inventor
Cornelis Joseph Maria Melief
Wybe Martin Kast
Original Assignee
Univ Leiden
Seed Capital Investments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Seed Capital Investments filed Critical Univ Leiden
Application granted granted Critical
Publication of ATE183514T1 publication Critical patent/ATE183514T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT93913627T 1992-05-26 1993-05-18 Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten ATE183514T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92201510 1992-05-26

Publications (1)

Publication Number Publication Date
ATE183514T1 true ATE183514T1 (de) 1999-09-15

Family

ID=8210629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93913627T ATE183514T1 (de) 1992-05-26 1993-05-18 Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten

Country Status (11)

Country Link
US (1) US5679641A (de)
EP (1) EP0643726B1 (de)
JP (2) JPH08501280A (de)
AT (1) ATE183514T1 (de)
AU (1) AU681853B2 (de)
CA (1) CA2136624A1 (de)
DE (1) DE69326064T2 (de)
DK (1) DK0643726T3 (de)
ES (1) ES2139012T3 (de)
GR (1) GR3031919T3 (de)
WO (1) WO1993024525A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1421947A1 (de) * 1992-07-22 2004-05-26 The Trustees Of Princeton University P53 vakzine
FR2698367B1 (fr) * 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
SG49008A1 (en) * 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
EP0726941B1 (de) * 1993-08-06 2002-04-03 Epimmune Inc. Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl
FR2722207B1 (fr) * 1994-07-07 1996-09-27 Inst Nat Sante Rech Med Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules
AU712441B2 (en) 1994-12-14 1999-11-04 Scripps Research Institute, The In vivo activation of tumor-specific cytotoxic T cells
US5925799A (en) * 1996-03-12 1999-07-20 Abb Lummus Global Inc. Catalytic distillation and hydrogenation of heavy unsaturates in an olefins plant
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
JPH11507843A (ja) * 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
SE9604581D0 (sv) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
AU757658B2 (en) * 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801695D0 (sv) * 1998-05-14 1998-05-14 Karolinska Innovations Ab Inhibition of p53 function by a p53-derived peptide
ES2326146T3 (es) * 1998-06-17 2009-10-01 Idm Pharma, Inc. Peptidos de union a hla y sus usos.
EP1165144A2 (de) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Mit einem eigengen-wildtyp transduzierte dendritische zellen lösen starke antitumor immunantwort aus
TW410377B (en) * 1999-06-17 2000-11-01 Taiwan Semiconductor Mfg Method of planarization and the apparatus of the same
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
FR2794368A1 (fr) * 1999-10-07 2000-12-08 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
JP2003516131A (ja) * 1999-12-10 2003-05-13 エピミューン, インコーポレイテッド ペプチドおよび核酸組成物を使用する、p53に対する細胞性免疫応答の誘導
EP2322228B1 (de) * 2000-06-05 2018-01-10 Altor BioScience Corporation T-Zell-Rezeptor Fusionsproteine und Konjugate und Verfahren zu deren Verwendung
DE10109855A1 (de) * 2001-03-01 2002-09-12 Stanislawski Thomas Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
WO2004018619A2 (en) * 2001-06-05 2004-03-04 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
US7179784B2 (en) * 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
US20040115216A1 (en) * 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
WO2006124700A2 (en) * 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
CA2662798A1 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2008021160A2 (en) * 2006-08-17 2008-02-21 Trustees Of Boston University Regulation of litaf modulated cytokine production by a novel p53 short peptide
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (de) 2007-03-28 2016-10-19 President and Fellows of Harvard College Geheftete Polypeptide
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. ペプチド模倣大環状分子およびその製剤
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
JP7391015B2 (ja) * 2017-09-29 2023-12-04 アメリカ合衆国 P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2021087840A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet

Also Published As

Publication number Publication date
EP0643726A1 (de) 1995-03-22
DK0643726T3 (da) 2000-03-20
CA2136624A1 (en) 1993-12-09
AU4359193A (en) 1993-12-30
WO1993024525A1 (en) 1993-12-09
ES2139012T3 (es) 2000-02-01
EP0643726B1 (de) 1999-08-18
DE69326064D1 (de) 1999-09-23
JPH08501280A (ja) 1996-02-13
US5679641A (en) 1997-10-21
AU681853B2 (en) 1997-09-11
DE69326064T2 (de) 2000-05-25
JP2004123708A (ja) 2004-04-22
GR3031919T3 (en) 2000-03-31

Similar Documents

Publication Publication Date Title
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
AU7197096A (en) Peptides of human papilloma virus for use in human T cell response inducing compositions
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
AU2987695A (en) Interruption of binding of mdm2 and p53 protein and therapeutic application thereof
ZA891861B (en) Monoclonal antibodies
TR199900666T2 (xx) �nsan paratormonu ile ilgili peptidlere kar�� antikor.
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
AU9291198A (en) Apoptosis-related compounds and their use
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
GR3035152T3 (en) Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
GR3001922T3 (en) Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE3462692D1 (en) Pharmacologically active peptides
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
NZ335136A (en) Isolated peptides which complex with hla-cw*16 molecules, and uses thereof
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
DE69631624D1 (de) Antikörper gegen menschliches restrictin
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
UA9703A (uk) Антипротеіназний засіб
MX9700199A (es) Composiciones de cadena invariante utiles para tratar enfermedades autoinmunes.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee